U.S. PENNSAID SALES CONTINUE TO GROW

_{//health-fitness.news-articles.net/content/2011/01/10/u-s-pennsaid-sales-continue-to-grow.html}
^{Published in Health and Fitness on Monday, January 10th 2011 at 4:11 GMT by Market Wire}  

U.S. PENNSAID SALES CONTINUE TO GROW

MISSISSAUGA, ON, Jan. 10 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.

In preparation for these meetings, Nuvo has updated its investor presentation which can be found on Nuvo's website at [ www.nuvoresearch.com ].

The presentation includes updated Pennsaid prescription data that shows U.S. prescriptions for Pennsaid in the fourth quarter of 2010 are tracking approximately 20% higher than the third quarter of 2010. Final third quarter prescriptions were 26,600.

About Nuvo Research Inc.

Nuvo is primarily focused on the research and development of drug products delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10. Nuvo's lead product is Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID), which is sold in Canada, the United States and several European countries. Pennsaid was approved for marketing in the U.S. by the United States Food and Drug Administration on November 4, 2009 and is being sold throughout the United States by Nuvo's licensing partner, Mallinckrodt Inc., a Covidien (NYSE: COV) company. Nuvo intends to create a portfolio of products through internal research and development and by in-licensing and acquisition. Nuvo is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario. Nuvo's Pain Group is located in West Chester, Pennsylvania. Its manufacturing facilities are located in Varennes, Québec and Wanzleben, Germany, and its research and development centers are located in San Diego, California and Leipzig, Germany. For more information, please visit [ www.nuvoresearch.com ]

Forward-Looking Statements

This document contains forward-looking statements. Some forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates" or similar expressions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Nuvo considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report, as well as in Nuvo's Annual Information Form for the year ended December 31, 2009. Nuvo disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information or future events, except as required by law. For additional information on risks and uncertainties relating to these forward looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other filings found on SEDAR at [ www.sedar.com ]

SOURCE Nuvo Research Inc.